“Accordingly, pursuant to the above Stipulation, and upon the consent and request of Plaintiffs and Amneal, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT: 1. The filing of ANDA 217289 was an act of infringement of the ’504 Patent under 35 U.S.C. § 271(e)(2)(A). 2. All other claims, counterclaims, and defenses asserted by the parties against each other in Plaintiffs’ and Amneal’s pleadings in the Action, including the allegations and averments contained therein are hereby dismissed, without prejudice. 3. Amneal, its officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell, or selling within the United States, or importing into the United States, the generic bimatoprost ophthalmic solution (0.01%) product described by ANDA 217289 during the life of Case 2:23-cv-06208-NJC-ST Document 133 Filed 09/11/25 Page 2 of 4 PageID #: 14740 the ’504 Patent including any extensions and pediatric exclusivities thereof, absent a license agreement or other authorization by Plaintiffs. 4. Plaintiffs and Amneal each expressly waive any right to appeal or otherwise move for relief from this Stipulation And Order. 5. This Court retains jurisdiction over Plaintiffs and Amneal for purposes of enforcing this Stipulation And Order. 6. This Stipulation And Order shall finally resolve the Action between the Parties. 7. This Stipulation And Order is without prejudice to any claim, defense, or counterclaim in any possible future action between Amneal and any of the Plaintiffs regarding the ’504 Patent and a product other than generic bimatoprost ophthalmic solution (0.01%) product described by ANDA 217289.”